A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study
2021 · BioDrugs · 21 citations
https://doi.org/10.1007/s40259-021-00482-x
E
Elisabetta Lolli
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
155
Papers
847
Citations
17
h-index
19
i10-index
Elisabetta Lolli is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Autoimmune and Inflammatory Disorders. The author has an h-index of 17, co-authored 132 publications.
ORCID: 0000-0003-1267-542XPapers by this author
worksEffect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study
2024 · Digestive Diseases and Sciences · 4 citations
https://doi.org/10.1007/s10620-024-08394-w
High Smad7 marks inflammation in patients with chronic pouchitis
2025 · Frontiers in Immunology · 2 citations
https://doi.org/10.3389/fimmu.2025.1549193
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat